Skip to main content
Premium Trial:

Request an Annual Quote

New Partnership Enables TranSMART Platform to be Offered on BT Life Sciences Cloud


The TranSMART Foundation and BT have forged a partnership that allows the latest version of the TranSMART knowledge management platform — an open source data sharing and analytics system (BI 6/7/2013) — to be offered on the BT for Life Sciences cloud infrastructure — a service the telecommunications giant launched last year to support scientists from pharmaceutical, biotechnology, devices, and diagnostics companies, as well as those in academia and government (BI 4/27/2012).

Michael Braxenthaler, the TranSMART foundation's co-CEO, said in a statement that BT will host a publically-accessible version of the current incarnation of tranSMART — version 1.1 — that "will provide a rich data environment for exploring the capabilities of the tranSMART platform." This will include tools for sharing integrating, standardizing, and analyzing heterogeneous translational research data.

Also for an undisclosed fee, BT will "provide a straightforward 'click-to-deploy' service for organizations that choose to partner with cloud providers for infrastructure services," Braxenthaler said.

Commenting on the partnership, Bas Burger, president of BT Global Services' North American and Global Industry Verticals, described it as "an important milestone for [his company's] life science ecosystem," one that lines up with BT's efforts to contribute to the drug discovery and development arena.

Brian Athey, co-CEO of the TranSMART Foundation, added that the BT partnership is "the first of many strategic relationships the Foundation will be forming to optimize our community's data sharing solution and to advance translational medicine research."

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.